Clene (CLNN) Competitors $3.60 -0.05 (-1.37%) Closing price 04:00 PM EasternExtended Trading$3.60 0.00 (-0.14%) As of 07:37 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock CLNN vs. CRDL, CRBP, CNTB, ALTS, TNYA, ATOS, SKYE, HURA, ZURA, and SAVAShould you be buying Clene stock or one of its competitors? The main competitors of Clene include Cardiol Therapeutics (CRDL), Corbus Pharmaceuticals (CRBP), Connect Biopharma (CNTB), ALT5 Sigma (ALTS), Tenaya Therapeutics (TNYA), Atossa Genetics (ATOS), Skye Bioscience (SKYE), TuHURA Biosciences (HURA), Zura Bio (ZURA), and Cassava Sciences (SAVA). These companies are all part of the "pharmaceutical products" industry. Clene vs. Its Competitors Cardiol Therapeutics Corbus Pharmaceuticals Connect Biopharma ALT5 Sigma Tenaya Therapeutics Atossa Genetics Skye Bioscience TuHURA Biosciences Zura Bio Cassava Sciences Cardiol Therapeutics (NASDAQ:CRDL) and Clene (NASDAQ:CLNN) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, risk, valuation, analyst recommendations, media sentiment, earnings, dividends and profitability. Which has more volatility & risk, CRDL or CLNN? Cardiol Therapeutics has a beta of 1.05, indicating that its share price is 5% more volatile than the S&P 500. Comparatively, Clene has a beta of 0.55, indicating that its share price is 45% less volatile than the S&P 500. Does the media refer more to CRDL or CLNN? In the previous week, Cardiol Therapeutics and Cardiol Therapeutics both had 8 articles in the media. Cardiol Therapeutics' average media sentiment score of 0.89 beat Clene's score of -0.19 indicating that Cardiol Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cardiol Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Clene 0 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do analysts recommend CRDL or CLNN? Cardiol Therapeutics presently has a consensus target price of $8.00, suggesting a potential upside of 497.01%. Clene has a consensus target price of $40.00, suggesting a potential upside of 1,011.11%. Given Clene's higher probable upside, analysts clearly believe Clene is more favorable than Cardiol Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cardiol Therapeutics 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 3.33Clene 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 3.17 Which has better valuation & earnings, CRDL or CLNN? Cardiol Therapeutics has higher earnings, but lower revenue than Clene. Cardiol Therapeutics is trading at a lower price-to-earnings ratio than Clene, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCardiol TherapeuticsN/AN/A-$26.77M-$0.34-3.94Clene$340K87.56-$39.40M-$4.04-0.89 Do insiders & institutionals believe in CRDL or CLNN? 12.5% of Cardiol Therapeutics shares are held by institutional investors. Comparatively, 23.3% of Clene shares are held by institutional investors. 5.3% of Cardiol Therapeutics shares are held by insiders. Comparatively, 35.3% of Clene shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth. Is CRDL or CLNN more profitable? Cardiol Therapeutics has a net margin of 0.00% compared to Clene's net margin of -8,306.00%. Clene's return on equity of 0.00% beat Cardiol Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Cardiol TherapeuticsN/A -209.63% -141.09% Clene -8,306.00%N/A -105.11% SummaryClene beats Cardiol Therapeutics on 8 of the 14 factors compared between the two stocks. Get Clene News Delivered to You Automatically Sign up to receive the latest news and ratings for CLNN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CLNN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CLNN vs. The Competition Export to ExcelMetricCleneMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$30.17M$3.10B$5.62B$9.84BDividend YieldN/A2.23%4.61%4.07%P/E Ratio-0.8920.4930.2925.74Price / Sales87.56356.37463.41115.83Price / CashN/A43.0338.2159.48Price / Book-3.408.608.826.15Net Income-$39.40M-$54.65M$3.25B$265.06M7 Day Performance-1.91%5.43%4.05%2.80%1 Month Performance-3.49%6.75%4.32%1.68%1 Year Performance-27.42%31.59%36.25%29.59% Clene Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CLNNClene3.2104 of 5 stars$3.60-1.4%$40.00+1,011.1%-28.0%$30.17M$340K-0.89100News CoverageEarnings ReportUpcoming EarningsAnalyst ForecastGap DownCRDLCardiol Therapeutics2.5223 of 5 stars$1.28-7.2%$8.00+525.0%-46.9%$114.09MN/A0.0020News CoverageEarnings ReportAnalyst RevisionGap UpHigh Trading VolumeCRBPCorbus Pharmaceuticals4.2995 of 5 stars$9.34+0.3%$49.38+428.6%-81.9%$113.92MN/A0.0040CNTBConnect Biopharma3.3203 of 5 stars$2.04+2.0%$7.00+243.1%+98.3%$111.12M$26.03M0.00110News CoveragePositive NewsAnalyst ForecastShort Interest ↓ALTSALT5 Sigma0.6327 of 5 stars$6.81+8.4%N/A+276.2%$109.61M$12.53M0.00170Trending NewsOptions VolumeGap UpTNYATenaya Therapeutics3.0232 of 5 stars$0.69+3.4%$6.25+801.5%-71.8%$109.08MN/A-0.60110Analyst RevisionATOSAtossa Genetics2.7094 of 5 stars$0.83+1.3%$6.17+639.7%-39.5%$106.31MN/A0.008News CoverageEarnings ReportSKYESkye Bioscience1.649 of 5 stars$3.63+6.5%$16.60+357.3%-24.3%$105.62MN/A0.0011News CoverageEarnings ReportAnalyst ForecastHURATuHURA Biosciences1.8902 of 5 stars$2.59+7.9%$12.67+389.1%N/A$104.83MN/A0.00N/ANews CoverageGap UpZURAZura Bio3.8392 of 5 stars$1.46-2.7%$14.33+881.7%-51.7%$102.56MN/A0.003News CoveragePositive NewsEarnings ReportSAVACassava Sciences2.0659 of 5 stars$2.29+8.0%$54.50+2,279.9%-90.5%$102.41MN/A0.0030News CoverageEarnings ReportGap Down Related Companies and Tools Related Companies CRDL Competitors CRBP Competitors CNTB Competitors ALTS Competitors TNYA Competitors ATOS Competitors SKYE Competitors HURA Competitors ZURA Competitors SAVA Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CLNN) was last updated on 8/14/2025 by MarketBeat.com Staff From Our PartnersMusk’s Project Colossus could mint millionairesI predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new milliona...Brownstone Research | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredWhen the levee breaksThe U.S. Treasury just confirmed it plans to borrow $1.01 trillion this quarter—nearly double what was project...Porter & Company | SponsoredBut this $20 American company could control the secretThe "Impossible" Chip That Runs on Pure Light Google's quantum computer shocked the world... but China DEMO...The Oxford Club | SponsoredUtah’s New Oil FindThe Real Reason 218,000 Acres Just Vanished The government just quietly leased 218,000 acres in the middle ...Stansberry Research | SponsoredGenerate up to $5,000/month with 10X less money?The secret to retiring without a million-dollar nest egg. I'm talking about generating enough monthly inco...Investors Alley | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Clene Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Clene With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access